Group items tagged

Summer flu is a viral infection that is caused by influenza viruses A and B. Flu symptoms were pain, chills, fever, and cough or throat irritation. Influenza is common during the winter months, but you can catch the flu at any time of year, even in summer. Consequences of the summer flu are not only for digestive system are affected and joint system, the endocrine system and the formation of lasting immunodeficiency. This is at full strength for children under ten years of age and older with long-term chronic diseases.

In a significant leap forward in the fight against HIV, the Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to two groundbreaking formulations of cabotegravir. Apretude 30 mg film-coated tablets and Apretude 600 mg prolonged-release suspension for injection are now authorized for preventing sexually transmitted HIV-1 infection in adults and adolescents weighing at least 35kg at increased risk. This approval marks a pivotal moment in HIV (human immunodeficiency virus) prevention, offering an alternative to existing standard pre-exposure prophylaxis or PrEP treatments. HIV, a virus notorious for compromising the immune system, has long been a global health concern. Cabotegravir, a member of the integrase inhibitor group, works by blocking a key enzyme necessary for the replication of HIV-1, thereby reducing the virus's ability to spread.

Small but significant breakthrough studies on people who have been able to overcome or control HIV were presented at a major world conference on ways to stem the three-decade-old disease. One study focused on a group of 12 patients in France who began treatment on antiretroviral drugs within 10 weeks of becoming infected with human immunodeficiency virus, but then stopped the therapy after nearly three years.

The 2011 report presents expanded analyses of care received by older Americans. It also addresses six priority areas for quality improvement, as identified in the National Strategy for Quality Improvement in Health Care report and presents novel strategies for improving quality and reducing disparities from AHRQ's Health Care Innovations Exchange.

The National Institute for Health and Care Excellence (NICE)'s independent committee has called for more research to ensure liposuction for treatment of chronic lipoedema is safe and effective enough for use on the NHS. Lipoedema is more prevalent in women and very rarely affects men. It is characterised by an abnormal, usually symmetrical, accumulation of fat in the legs, hips, buttocks, and occasionally arms. It is a separate condition to obesity and lymphoedema. The cause of lipoedema is unknown, but hormonal changes, weight gain and genetics are thought to be involved. The size and shape of legs, and the resultant mobility issues and pain, can have a profoundly negative effect on quality of life, and physical and mental health. The interventional procedures advisory committee reviewed evidence from several sources, including eight before-and-after studies. The committee was informed that several different liposuction techniques are used and that they may have different safety and efficacy profiles.